Interestingly, it has recently been reported that a FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity,649 suggesting an attractive strategy for the therapy of T2DM and its complications. Here, GPBAR1 is linked to type 2 diabetes mellitus.